---
title: Evaluation of Surgical Complications and DFS in Obese Rectal Cancer Patients
nct_id: NCT06056726
overall_status: UNKNOWN
sponsor: Federico II University
study_type: OBSERVATIONAL
primary_condition: Obesity, Morbid
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06056726.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06056726"
ct_last_update_post_date: 2023-09-29
last_seen_at: "2026-05-12T06:45:26.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Surgical Complications and DFS in Obese Rectal Cancer Patients

**Official Title:** Evaluation of Intra- and Peri-operative Complications and Disease-free Survival in Rectal Cancer Patients Undergoing Oncological Resective Surgery and Concomitant Bariatric Surgery

**NCT ID:** [NCT06056726](https://clinicaltrials.gov/study/NCT06056726)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Federico II University
- **Conditions:** Obesity, Morbid, Rectal Cancer, Surgery-Complications
- **Start Date:** 2021-02-18
- **Completion Date:** 2025-02-18
- **CT.gov Last Update:** 2023-09-29

## Brief Summary

Obesity worsens treatment outcomes in rectal cancer patients: the local resective approach could in fact be more difficult in obese patients due to limited surgical visibility and it has also been reported that high visceral adiposity determines an increased risk of recurrence after chemoradiotherapy neoadjuvant. Bariatric surgery has proved to be the best choice for the treatment of morbid obesity and related comorbidities and in this context, the intragastric balloon (IGB) represents a strategy characterized by a low rate of complications and good results in terms of weight loss.

Therefore, the need to be able to offer obese patients suffering from rectal cancer the possibility of a better recovery perspective, alongside radical oncological surgery and neoadjuvant treatments, also a bariatric surgery such as the positioning of an intragastric balloon.

## Detailed Description

Epidemiological data show that obesity is associated with a 30-70% increase in the risk of developing rectal cancer; Obesity could also be associated with a worsening of the tumor prognosis, with an increased risk of recurrence and increased mortality. From this point of view, recent studies have shown that a BMI ≥ 30 kg/m2 is associated with higher oncological and functional risks in patients with locally advanced rectal cancer, with lower response rates to neoadjuvant treatment and a less frequent preservation of the anal sphincter.

Obesity also worsens treatment outcomes: the local resective approach could in fact be more difficult in obese patients due to limited surgical visibility and it has also been reported that high visceral adiposity determines an increased risk of recurrence after chemoradiotherapy neoadjuvant. Bariatric surgery has proved to be the best choice for the treatment of morbid obesity and related comorbidities and in this context, the intragastric balloon (IGB) represents a strategy characterized by a low rate of complications and good results in terms of weight loss.

The most recent studies on the subject have shown that IGBs are effective in producing weight loss ranging from 6% to 15% compared to 1% -5% produced by lifestyle interventions alone Therefore, the need to be able to offer obese patients suffering from rectal cancer the possibility of a better recovery perspective (reduction of intra- and peri-operative complications, increased disease-free survival and lower risk of long-term recurrence) is underlined. ), alongside radical oncological surgery and neoadjuvant treatments, also a bariatric surgery such as the positioning of an intragastric balloon.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with locally advanced rectal cancer in clinical stage II-III according to AJCC-UICC 2017 (candidates for neoadjuvant therapy)
* Patients suffering from I, II and III degree obesity at the same time
* Age between 18 and 70 years old
* BMI between 31 and 55 kg/m2
* Non-Smoking
* Candidates, according to AIOM guidelines, for rectal resection surgical procedures
* Candidates, according to SICOB guidelines, for an intragastric balloon placement procedure

Exclusion Criteria:

* Age ≤ 18 or ≥ 70 years
* BMI ≤ 30 or ≥ 59 Kg/m2
* Smoker
* Patients with non-locally advanced rectal cancer, not eligible for neoadjuvant therapy
* Histological positivity to Helicobacter pylori
* Presence of ulcerative lesions on EGD
* Previous bariatric surgery treatments
```

## Arms

- **Obese Patients** — Patients candidates for resective surgery for rectal cancer and also elegible for bariatric surgery

## Interventions

- **BIB positioning** (PROCEDURE) — BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy

## Primary Outcomes

- **Peri-operative complications** _(time frame: Intra-operative complications and complications within 30 days from surgery)_ — Peri-operative complications during rectal cancer surgery

## Secondary Outcomes

- **Overall survival** _(time frame: 3 years after surgery)_

## Locations (1)

- Nunzio Velotti, Naples, Italy — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.nunzio velotti|naples||italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06056726.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06056726*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*